

# Accepted Manuscript

Prevalence of the ACC/AHA statin eligibility groups, statin use and low-density lipoprotein cholesterol (LDL-C) control in US adults using the National Health and Nutrition Examination Survey 2011–2012

Nathan D. Wong, PhD, Daphnee Young, BS, Yanglu Zhao, MD, MS, Huy Nguyen, BS, Jared Caballes, BS, Irfan Khan, PhD, Robert J. Sanchez, PhD

PII: S1933-2874(16)30230-6

DOI: [10.1016/j.jacl.2016.06.011](https://doi.org/10.1016/j.jacl.2016.06.011)

Reference: JACL 955

To appear in: *Journal of Clinical Lipidology*

Received Date: 8 February 2016

Revised Date: 15 June 2016

Accepted Date: 21 June 2016

Please cite this article as: Wong ND, Young D, Zhao Y, Nguyen H, Caballes J, Khan I, Sanchez RJ, Prevalence of the ACC/AHA statin eligibility groups, statin use and low-density lipoprotein cholesterol (LDL-C) control in US adults using the National Health and Nutrition Examination Survey 2011–2012, *Journal of Clinical Lipidology* (2016), doi: 10.1016/j.jacl.2016.06.011.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Prevalence of the ACC/AHA statin eligibility groups, statin use and low-density lipoprotein cholesterol (LDL-C) control in US adults using the National Health and Nutrition Examination Survey 2011–2012**

Running Title: Statin use and LDL-C control in US Adults

Nathan D. Wong PhD,<sup>1</sup> Daphnee Young, BS<sup>1</sup> Yanglu Zhao, MD, MS<sup>1</sup> Huy Nguyen, BS<sup>1</sup> Jared Caballes, BS<sup>1</sup> Irfan Khan, PhD<sup>2</sup> and Robert J. Sanchez, PhD<sup>3</sup>

From the Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine and Global Health Economics and Outcomes Research;<sup>1</sup> Sanofi, Bridgewater, NJ, USA;<sup>2</sup> and Regeneron Pharmaceuticals Inc., Tarrytown NY, USA<sup>3</sup>

Correspondence to Dr. Nathan Wong at Heart Disease Prevention Program, C240 Medical Sciences, University of California, Irvine, CA 92697-4101 USA email: [ndwong@uci.edu](mailto:ndwong@uci.edu).

Download English Version:

<https://daneshyari.com/en/article/5615408>

Download Persian Version:

<https://daneshyari.com/article/5615408>

[Daneshyari.com](https://daneshyari.com)